{
    "clinical_study": {
        "@rank": "100763", 
        "arm_group": [
            {
                "arm_group_label": "S-1 + cisplatin(SP)", 
                "arm_group_type": "Active Comparator", 
                "description": "S-1\uff1a40~60mg bid\uff0cd1~14 q3W cisplatin\uff1a60mg/m2\uff0civ drip \uff0cd1,q3W Number of Cycles: until progression or unacceptable toxicity develops."
            }, 
            {
                "arm_group_label": "S-1+Oxaliplatin\uff08SOX\uff09", 
                "arm_group_type": "Experimental", 
                "description": "S-1\uff1a40~60mg bid\uff0cd1~14 q3W oxaliplatin\uff1a130mg/m2\uff0civ drip for 2h\uff0cd1,q3W Number of Cycles: until progression or unacceptable toxicity develops."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin\n      vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric\n      Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients."
        }, 
        "brief_title": "S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Diffuse Gastric Adenocarcinoma Patients", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary endpoint is Overall survival time (OS).Secondary is overall response rate (ORR),\n      time to treatment failure (TTF),treatment to progression time (TTP)and the adverse reactions\n      of the two groups (AE)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. histologically confirmed unresectable advanced or recurrent diffuse-type gastric\n             adenocarcinoma or gastroesophageal junction adenocarcinoma.\n\n          2. 18 years old to 75 years old, able to conduct oral administration.\n\n          3. Measurable disease, according to the Response Evaluation Criteria in Solid\n             Tumours(RECIST 1.1)\uff0cexcept non-measurable but evaluable disease,such as peritoneal\n             metastasis\n\n          4. No palliative chemotherapy and radiotherapy. Previous adjuvant or neoadjuvant\n             chemotherapy , if applicable, more than 12 months.\n\n          5. ECOG systemic status score of 0 to 2.\n\n          6. normal organ function, that meet the following criteria:\n\n               1. ALT and AST<2.5 times ULN (\u22645 times ULN in patients with liver metastases)\n\n               2. ALP \u2264 2 times ULN ; (for patients with liver metastases can be no limit to the\n                  ALP).\n\n               3. Total bilirubin \u2264 1 times ULN.\n\n               4. Absolute neutrophil count \u2265 2.0 \u00d7 10 9 / L.\n\n               5. Platelet count \u2265 100 \u00d7 10 9 / L.\n\n               6. Hemoglobin \u2265 80g / L.\n\n               7. Creatinine \u2264 1.25 times ULN.\n\n               8. The estimated creatinine clearance \u2265 60 mL/min (Cockcroft-Gault formula).\n\n          7. signed informed consent, treatment, follow-up and inspection in accordance with the\n             study protocol.\n\n          8. life expectancy greater than 3 months.\n\n          9. at least 3 weeks after major surgery.\n\n        Exclusion Criteria:\n\n          1. Previous adjuvant or neoadjuvant chemotherapy within the prescribed time\n\n          2. the investigator determines that the patient is not suitable for participation in\n             this study, and specifically includes (but is not limited to):\n\n               1. The past five years there have been other malignancies, but after appropriate\n                  treatment of cervical carcinoma in situ and non-melanoma skin cancer.\n\n               2. brain metastases or leptomeningeal metastasis.\n\n               3. myocardial infarction (within the past six months), severe unstable angina,\n                  congestive heart failure.\n\n               4. Serious complications (including paralytic ileus, intestinal obstruction,\n                  interstitial pneumonia, lung fibrosis, beyond the control of diabetes, renal\n                  insufficiency and cirrhosis of the liver, etc.).\n\n               5. Chronic nausea, vomiting, or diarrhea (per day greater than or equal to 4 times\n                  or watery stools).\n\n               6. Gastrointestinal bleeding, and need for frequent blood transfusions.\n\n               7. human immunodeficiency virus (HIV) carrier or suffering from AIDS (AIDS).\n\n               8. Suffering from a mental illness.\n\n               9. neuropathy severity \u2265grade 2 .\n\n              10. Infectious disease or inflammation, body temperature \u2265 38 \u2103.\n\n          3. Cisplatin, oxaliplatin, or S-1 allergy.\n\n          4. Pregnancy or breast-feeding women.\n\n          5. refused to take appropriate contraceptive measures (including male patients).\n\n          6. Under experimental drug within 4 weeks.\n\n          7. Under other anti-cancer treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "446", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824459", 
            "org_study_id": "SOX-DGCA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "S-1 + cisplatin(SP)", 
                    "S-1+Oxaliplatin\uff08SOX\uff09"
                ], 
                "description": "S-1\uff1a40~60mg bid\uff0cd1~14 q3W", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S-1+Oxaliplatin\uff08SOX\uff09", 
                "description": "oxaliplatin\uff1a130mg/m2\uff0civ drip for 2h\uff0cd1,q3W", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S-1 + cisplatin(SP)", 
                "description": "cisplatin\uff1a60mg/m2\uff0civ drip \uff0cd1,q3W", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diffuse-type gastric cancer", 
            "Advance Gastric Cancer", 
            "Recurrent  Gastric Cancer", 
            "Gastroesophageal Junction Adenocarcinoma", 
            "SOX, S-1+Oxaliplatin", 
            "OS,", 
            "ORR,", 
            "TTP,", 
            "TTF,", 
            "safety"
        ], 
        "lastchanged_date": "April 1, 2013", 
        "location": {
            "contact": {
                "email": "xurh@sysucc.org.cn", 
                "last_name": "Ruihua Xu, Professor", 
                "phone": "862087343228"
            }, 
            "contact_backup": {
                "email": "liyuhong@mail.sysu.edu.cn", 
                "last_name": "Yuhong Li, Professor", 
                "phone": "13602755671"
            }, 
            "facility": {
                "address": {
                    "city": "Gaungzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients", 
        "overall_contact": {
            "email": "xurh@sysucc.org.cn", 
            "last_name": "Ruihua xu, Professor", 
            "phone": "862087343228"
        }, 
        "overall_contact_backup": {
            "email": "liyuhong@mail.sysu.edu.cn", 
            "last_name": "yuhong li, Professor", 
            "phone": "13602755671"
        }, 
        "overall_official": {
            "affiliation": "SunYat-sen University Cancer Center", 
            "last_name": "ruihua xu, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost", 
            "measure": "Overall Survival", 
            "safety_issue": "Yes", 
            "time_frame": "1-1.5 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824459"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Ruihua Xu", 
            "investigator_title": "vice president of SunYat-sen University Cancer Center,head of medical oncology department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The primary endpoint is objective response rate,which equals CR+PR.", 
                "measure": "Objective response rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The duration is from the randomized time to treatment termination due to any reason. The reasons may include disease progression, treatment toxicity, patient selection or death.", 
                "measure": "time to treatment failure (TTF)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The duration is from the radomized time to disease progression due to any reason except death .", 
                "measure": "Treatment time to progression (TTP)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "1-1.5 years"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}